Capell WH, Bonaca MP, Nehler MR, et al. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018;199:83-91.
DOI: 10.1016/j.ahj.2018.01.011
Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020;382(21):1994-2004.
DOI: 10.1056/NEJMoa2000052
Bauersachs RM, Szarek M, Brodmann M, et al. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. J Am Coll Cardiol. 2021;78(4):317-326.
DOI: 10.1016/j.jacc.2021.05.003
Berkowitz SD, Bauersachs RM, Szarek M, et al. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. J Thromb Haemost. 2022;20(5):1193-1205.
DOI: 10.1111/jth.15673
Hiatt WR, Bonaca MP, Patel MR, et al. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation. 2020;142(23):2219-2230.
DOI: 10.1161/CIRCULATIONAHA.120.050465
Bosch J, Eikelboom JW, Connolly SJ, et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027-1035.
DOI: 10.1016/j.cjca.2017.06.001
Anand SS, Caron F, Eikelboom JW, et al. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. J Am Coll Cardiol. 2018;71(20):2306-2315.
DOI: 10.1016/j.jacc.2018.03.008
Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2018;391(10117):219-229.
DOI: 10.1016/S0140-6736(17)32409-1
Steffel J, Eikelboom JW, Anand SS, Shestakovska O, Yusuf S, Fox KAA. The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation. 2020;142(1):40-48.
DOI: 10.1161/CIRCULATIONAHA.120.046048
Kaplovitch E, Eikelboom JW, Dyal L, et al. Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiol. 2021;6(1):21-29.
Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330.
DOI: 10.1056/NEJMoa1709118
Ebertz DP, Bose S, Smith JA, et al. Use of direct-acting oral anticoagulants associated with improved survival and bypass graft patency compared with warfarin after infrageniculate bypass. J Vasc Surg. 2023;77(5):1453-1461.
DOI: 10.1016/j.jvs.2022.12.012